Intellia Therapeutics (NTLA) EBITDA Margin (2015 - 2026)
Intellia Therapeutics' (NTLA) quarterly EBITDA Margin came in at 668.08% in Q1 2026, up 5850.0% year-on-year from 11.23% in Q1 2025, and down 55.78% on a QoQ basis from 428.86% in Q4 2025.
Intellia Therapeutics (NTLA) EBITDA Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of EBITDA Margin data on file, last reported at 668.08% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 5850.0% year-over-year to 668.08% in Q1 2026; TTM through Mar 2026 was 636.56%, a 55080.0% increase from a year earlier, with the FY2025 full-year figure at 651.67%, up 27143.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 668.08%, down from 428.86% in the prior quarter.
- Over the last five years, EBITDA Margin for NTLA reached as high as 7297.44% in Q4 2023 and fell as low as 1998.61% in Q2 2024.
- Historically, EBITDA Margin has averaged 452.5% across 5 years, with a median of 808.86% in 2025.
- Across the five-year window, EBITDA Margin jumped 810852 bps in 2023 and sank 835731 bps in 2024, its largest moves.
- Year by year, EBITDA Margin stood at 811.07% in 2022, then jumped by 1000 bps to 7297.44% in 2023, then slumped by 115 bps to 1059.86% in 2024, then surged by 60 bps to 428.86% in 2025, then sank by 56 bps to 668.08% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 668.08% in Q1 2026, 428.86% in Q4 2025, and 808.86% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Intellia Therapeutics | 1.32 Bn | 1.32 Bn | - | -668.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -668.08% |
| Dec 31, 2025 | -428.86% |
| Sep 30, 2025 | -808.86% |
| Jun 30, 2025 | -772.17% |
| Mar 31, 2025 | -726.57% |
| Dec 31, 2024 | -1,059.86% |
| Sep 30, 2024 | -1,588.96% |
| Jun 30, 2024 | -1,998.61% |
| Mar 31, 2024 | -394.00% |
| Dec 31, 2023 | 7,297.44% |
| Sep 30, 2023 | -1,093.29% |
| Jun 30, 2023 | -973.47% |
| Mar 31, 2023 | -888.13% |
| Dec 31, 2022 | -811.07% |
| Sep 30, 2022 | -795.49% |
| Jun 30, 2022 | -700.65% |
| Mar 31, 2022 | -1,281.96% |
| Dec 31, 2021 | -625.60% |
| Sep 30, 2021 | -999.35% |
| Jun 30, 2021 | -1,053.69% |